Down-regulation of A20 promotes immune escape of lung adenocarcinomas.

Adenocarcinoma of Lung / genetics Animals B7-H1 Antigen / genetics Down-Regulation Humans Interferon-gamma / metabolism Lung Neoplasms / genetics Mice Signal Transduction Tumor Necrosis Factor alpha-Induced Protein 3 / genetics

Journal

Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086

Informations de publication

Date de publication:
07 07 2021
Historique:
received: 22 04 2020
revised: 15 02 2021
accepted: 02 06 2021
entrez: 8 7 2021
pubmed: 9 7 2021
medline: 13 7 2021
Statut: ppublish

Résumé

Inflammation is a well-known driver of lung tumorigenesis. One strategy by which tumor cells escape tight homeostatic control is by decreasing the expression of the potent anti-inflammatory protein tumor necrosis factor alpha-induced protein 3 (TNFAIP3), also known as A20. We observed that tumor cell intrinsic loss of A20 markedly enhanced lung tumorigenesis and was associated with reduced CD8

Identifiants

DOI: 10.1126/scitranslmed.abc3911 PMID: 34233950 PMC: PMC7611502
pubmed: 34233950
pii: 13/601/eabc3911
doi: 10.1126/scitranslmed.abc3911
pmc: PMC7611502
mid: EMS131902
pii:
doi:

Substances chimiques

B7-H1 Antigen 0
Interferon-gamma 82115-62-6
TNFAIP3 protein, human EC 3.4.19.12
Tumor Necrosis Factor alpha-Induced Protein 3 EC 3.4.19.12

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Austrian Science Fund FWF
ID : DOC 59
Pays : Austria
Organisme : Austrian Science Fund FWF
ID : P 33430
Pays : Austria
Organisme : Austrian Science Fund FWF
ID : F 4707
Pays : Austria
Organisme : Austrian Science Fund FWF
ID : F 6105
Pays : Austria
Organisme : Austrian Science Fund FWF
ID : I 4157
Pays : Austria
Organisme : Austrian Science Fund FWF
ID : I 4677
Pays : Austria
Organisme : Austrian Science Fund FWF
ID : I 3522
Pays : Austria
Organisme : Austrian Science Fund FWF
ID : P 32900
Pays : Austria
Organisme : Austrian Science Fund FWF
ID : P 25599
Pays : Austria
Organisme : Austrian Science Fund FWF
ID : I 3977
Pays : Austria

Informations de copyright

Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Références

Acta Neuropathol. 2013 Sep 29;126(5):711-724
pubmed: 24077734
J Immunol. 2016 Dec 1;197(11):4493-4503
pubmed: 27799309
PLoS One. 2013 Dec 18;8(12):e82241
pubmed: 24367507
Nat Cell Biol. 2017 Oct;19(10):1260-1273
pubmed: 28892081
Nature. 2018 Jan 24;553(7689):446-454
pubmed: 29364287
Immunity. 2012 Feb 24;36(2):166-74
pubmed: 22365663
Nat Commun. 2017 May 31;8:15440
pubmed: 28561041
Clin Cancer Res. 2018 Aug 15;24(16):3857-3866
pubmed: 29716923
Nat Rev Immunol. 2012 Nov;12(11):774-85
pubmed: 23059429
Cancer Discov. 2019 Jan;9(1):34-45
pubmed: 30297358
Nat Immunol. 2004 Oct;5(10):1052-60
pubmed: 15334086
Nature. 2009 Nov 5;462(7269):104-7
pubmed: 19847165
Clin Cancer Res. 2017 Jun 15;23(12):3012-3024
pubmed: 28039262
Cell Rep. 2020 Jan 14;30(2):481-496.e6
pubmed: 31940491
Biochem Biophys Res Commun. 2012 Feb 10;418(2):433-8
pubmed: 22285182
Nat Commun. 2016 Sep 02;7:12685
pubmed: 27585860
Nat Med. 2013 Mar;19(3):313-21
pubmed: 23396211
Cancer Res. 2010 May 1;70(9):3537-46
pubmed: 20406971
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
Cancer Discov. 2018 Jul;8(7):822-835
pubmed: 29773717
Clin Cancer Res. 2016 Sep 15;22(18):4585-93
pubmed: 27225694
Cancer Cell. 2020 Oct 12;38(4):500-515.e3
pubmed: 32916126
Mol Cell. 2011 Nov 18;44(4):559-71
pubmed: 22099304
Arthritis Res Ther. 2016 Oct 3;18(1):216
pubmed: 27716397
Cell. 2015 Jan 15;160(1-2):48-61
pubmed: 25594174
Clin Cancer Res. 2014 Oct 1;20(19):5064-74
pubmed: 24714771
J Biol Chem. 2010 May 14;285(20):14999-15009
pubmed: 20304918
Eur J Cancer. 2019 Jan;106:144-159
pubmed: 30528799
J Biomed Sci. 2017 Feb 1;24(1):10
pubmed: 28143527
J Biol Chem. 2014 Nov 7;289(45):30912-24
pubmed: 25217635
Cancer Cell. 2019 Feb 11;35(2):238-255.e6
pubmed: 30753825
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Nat Genet. 2016 Jan;48(1):67-73
pubmed: 26642243
PLoS Biol. 2010 Feb 23;8(2):e1000319
pubmed: 20186265
Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):E6409-E6417
pubmed: 27702896
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Cytokine. 2017 Jan;89:12-20
pubmed: 26631912
Eur J Immunol. 2011 Mar;41(3):595-601
pubmed: 21341261
J Transl Med. 2019 Nov 4;17(1):357
pubmed: 31684954
Cancer Cell. 2021 Feb 8;39(2):193-208.e10
pubmed: 33357452
Acta Oncol. 2019 Aug;58(8):1087-1094
pubmed: 31002007
PLoS One. 2013 May 06;8(5):e62223
pubmed: 23671587
Trends Immunol. 2020 May;41(5):421-435
pubmed: 32241683
Nat Rev Mol Cell Biol. 2001 May;2(5):378-86
pubmed: 11331912
Cancer Discov. 2017 Feb;7(2):188-201
pubmed: 27903500
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
J Exp Med. 2009 May 11;206(5):981-9
pubmed: 19380639
Nat Genet. 2008 Sep;40(9):1062-4
pubmed: 19165919
Nature. 2017 Nov 23;551(7681):517-520
pubmed: 29132144
Sci Rep. 2019 Sep 2;9(1):12658
pubmed: 31477755
Nature. 2015 Apr 30;520(7549):697-701
pubmed: 25901683
Cancer Discov. 2011 Aug;1(3):236-47
pubmed: 21874163
Immunity. 2016 Feb 16;44(2):343-54
pubmed: 26872698
Clin Cancer Res. 2016 Oct 1;22(19):4880-4889
pubmed: 27354471
J Biomed Sci. 2013 Oct 07;20:74
pubmed: 24099634
J Immunol. 2018 Oct 15;201(8):2273-2286
pubmed: 30209192
Immunity. 2019 Jul 16;51(1):27-41
pubmed: 31315034
Sci Rep. 2020 Jan 20;10(1):643
pubmed: 31959763
Genes Dev. 2001 Dec 15;15(24):3243-8
pubmed: 11751630
PLoS Biol. 2010 Apr 27;8(4):e1000361
pubmed: 20436908
FASEB J. 2015 May;29(5):1869-78
pubmed: 25667218
Cell. 2017 Nov 30;171(6):1301-1315.e14
pubmed: 29195074
Blood. 2006 Nov 15;108(10):3253-61
pubmed: 16868248
J Immunother Cancer. 2017 Feb 21;5:16
pubmed: 28239469
Genes Cancer. 2014 Apr;5(1-2):41-55
pubmed: 24955217
Cancer Cell. 2011 Jan 18;19(1):72-85
pubmed: 21251614

Auteurs

Kristina Breitenecker (K)

Institute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria.
Institute of Cancer Research, Medical University of Vienna, AT-1090 Vienna, Austria.
Comprehensive Cancer Center (CCC), Medical University of Vienna, AT-1090 Vienna, Austria.
ORCID: 0000-0002-5334-6377

Monika Homolya (M)

Institute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria.
ORCID: 0000-0002-0735-7710

Andreea C Luca (AC)

Institute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria.
ORCID: 0000-0003-1519-5464

Veronika Lang (V)

Institute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria.
ORCID: 0000-0001-9844-9153

Christoph Trenk (C)

Institute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria.
ORCID: 0000-0002-9754-181X

Georg Petroczi (G)

Institute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria.
ORCID: 0000-0003-3069-6013

Julian Mohrherr (J)

Institute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria.

Jaqueline Horvath (J)

Institute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria.
ORCID: 0000-0002-2031-5515

Stefan Moritsch (S)

Institute of Cancer Research, Medical University of Vienna, AT-1090 Vienna, Austria.
Comprehensive Cancer Center (CCC), Medical University of Vienna, AT-1090 Vienna, Austria.
ORCID: 0000-0002-1849-1616

Lisa Haas (L)

Research Institute of Molecular Pathology, Vienna Biocenter, AT-1030 Vienna, Austria.

Margarita Kurnaeva (M)

Institute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria.
ORCID: 0000-0002-9769-5982

Robert Eferl (R)

Institute of Cancer Research, Medical University of Vienna, AT-1090 Vienna, Austria.
Comprehensive Cancer Center (CCC), Medical University of Vienna, AT-1090 Vienna, Austria.
ORCID: 0000-0002-6074-7144

Dagmar Stoiber (D)

Institute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria.
Division Pharmacology, Department of Pharmacology, Physiology and Microbiology, Karl Landsteiner University of Health Sciences, AT-3500 Krems, Austria.
ORCID: 0000-0002-8824-0767

Richard Moriggl (R)

Institute of Animal Breeding and Genetics, University of Veterinary Medicine, AT-1210 Vienna, Austria.
ORCID: 0000-0003-0918-9463

Martin Bilban (M)

Department of Laboratory Medicine, Medical University of Vienna, AT-1090 Vienna, Austria.
Core Facilities, Medical University of Vienna, AT-1090 Vienna, Austria.
ORCID: 0000-0001-7043-7142

Anna C Obenauf (AC)

Research Institute of Molecular Pathology, Vienna Biocenter, AT-1030 Vienna, Austria.
ORCID: 0000-0002-9556-5914

Christiane Ferran (C)

Division of Vascular and Endovascular Surgery and the Center for Vascular Biology Research, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Transplant Institute and the Division of Nephrology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
ORCID: 0000-0002-3379-7998

Balazs Dome (B)

Division of Thoracic Surgery, Department of Surgery, and Comprehensive Cancer Center (CCC), Medical University of Vienna, AT-1090 Vienna, Austria.
1st Department of Tumor Biology, National Korányi Institute of Pulmonology, Semmelweis University, HU-1121 Budapest, Hungary.
Department of Thoracic Surgery, National Institute of Oncology and Semmelweis University, HU-1122 Budapest, Hungary.
ORCID: 0000-0001-8799-8624

Viktoria Laszlo (V)

Division of Thoracic Surgery, Department of Surgery, and Comprehensive Cancer Center (CCC), Medical University of Vienna, AT-1090 Vienna, Austria.
1st Department of Tumor Biology, National Korányi Institute of Pulmonology, Semmelweis University, HU-1121 Budapest, Hungary.
ORCID: 0000-0002-6567-3965

Balázs Győrffy (B)

MTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, and 2nd Department of Pediatrics, Semmelweis University, HU-1117 Budapest, Hungary.
Department of Bioinformatics, Semmelweis University, HU-1094 Budapest, Hungary.
2nd Department of Pediatrics, Semmelweis University, HU-1094 Budapest, Hungary.

Katalin Dezso (K)

1st Department of Pathology and Experimental Cancer Research, Semmelweis University, HU-1085 Budapest, Hungary.
ORCID: 0000-0002-4856-0483

Judit Moldvay (J)

1st Department of Pulmonology, National Korányi Institute of Pulmonology, HU-1121 Budapest, Hungary.
SE-NAP Brain Metastasis Research Group, 2nd Department of Pathology, Semmelweis University, HU-1122 Budapest, Hungary.
ORCID: 0000-0001-9425-1748

Emilio Casanova (E)

Institute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria.
Comprehensive Cancer Center (CCC), Medical University of Vienna, AT-1090 Vienna, Austria.
ORCID: 0000-0001-7992-5361

Herwig P Moll (HP)

Institute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria. herwig.moll@meduniwien.ac.at.
Comprehensive Cancer Center (CCC), Medical University of Vienna, AT-1090 Vienna, Austria.
ORCID: 0000-0001-6438-9068

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Tumeurs › Tumeurs par siège › Tumeurs du thorax › Adénocarcinome pulmonaire › Down-regulation of A20 promotes immune escape...
questionsmedicales.fr › Eucaryotes › Animaux › Down-regulation of A20 promotes immune escape...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Antigènes B7 › Antigène CD274 › Down-regulation of A20 promotes immune escape...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Régulation négative › Down-regulation of A20 promotes immune escape...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Down-regulation of A20 promotes immune escape...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Lymphokines › Facteurs d'activation des macrophages › Interféron gamma › Down-regulation of A20 promotes immune escape...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Down-regulation of A20 promotes immune escape...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Down-regulation of A20 promotes immune escape...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › Down-regulation of A20 promotes immune escape...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protéine-3 induite par le facteur de nécrose tumorale alpha › Down-regulation of A20 promotes immune escape...